175 related articles for article (PubMed ID: 35048559)
1. A Selective Small-Molecule c-Myc Degrader Potently Regresses Lethal c-Myc Overexpressing Tumors.
Xu Y; Yu Q; Wang P; Wu Z; Zhang L; Wu S; Li M; Wu B; Li H; Zhuang H; Zhang X; Huang Y; Gan X; Xu R
Adv Sci (Weinh); 2022 Mar; 9(8):e2104344. PubMed ID: 35048559
[TBL] [Abstract][Full Text] [Related]
2. Novel synthetic tosyl chloride-berbamine regresses lethal MYC-positive leukemia by targeting CaMKIIγ/Myc axis.
Yu Q; Wang P; Yang L; Wu Z; Li S; Xu Y; Wu B; Ma A; Gan X; Xu R
Biomed Pharmacother; 2019 Sep; 117():109134. PubMed ID: 31247466
[TBL] [Abstract][Full Text] [Related]
3. Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis.
Huang HL; Weng HY; Wang LQ; Yu CH; Huang QJ; Zhao PP; Wen JZ; Zhou H; Qu LH
Mol Cancer Ther; 2012 May; 11(5):1155-65. PubMed ID: 22389469
[TBL] [Abstract][Full Text] [Related]
4. MM-1 facilitates degradation of c-Myc by recruiting proteasome and a novel ubiquitin E3 ligase.
Kimura Y; Nagao A; Fujioka Y; Satou A; Taira T; Iguchi-Ariga SM; Ariga H
Int J Oncol; 2007 Oct; 31(4):829-36. PubMed ID: 17786314
[TBL] [Abstract][Full Text] [Related]
5. The ubiquitin ligase CHIP regulates c-Myc stability and transcriptional activity.
Paul I; Ahmed SF; Bhowmik A; Deb S; Ghosh MK
Oncogene; 2013 Mar; 32(10):1284-95. PubMed ID: 22543587
[TBL] [Abstract][Full Text] [Related]
6. Targeted destruction of c-Myc by an engineered ubiquitin ligase suppresses cell transformation and tumor formation.
Hatakeyama S; Watanabe M; Fujii Y; Nakayama KI
Cancer Res; 2005 Sep; 65(17):7874-9. PubMed ID: 16140957
[TBL] [Abstract][Full Text] [Related]
7. Identification of the HECT E3 ligase UBR5 as a regulator of MYC degradation using a CRISPR/Cas9 screen.
Schukur L; Zimmermann T; Niewoehner O; Kerr G; Gleim S; Bauer-Probst B; Knapp B; Galli GG; Liang X; Mendiola A; Reece-Hoyes J; Rapti M; Barbosa I; Reschke M; Radimerski T; Thoma CR
Sci Rep; 2020 Nov; 10(1):20044. PubMed ID: 33208877
[TBL] [Abstract][Full Text] [Related]
8. Proteolytic control of the oncoprotein transcription factor Myc.
Thomas LR; Tansey WP
Adv Cancer Res; 2011; 110():77-106. PubMed ID: 21704229
[TBL] [Abstract][Full Text] [Related]
9. A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function.
Rottmann S; Wang Y; Nasoff M; Deveraux QL; Quon KC
Proc Natl Acad Sci U S A; 2005 Oct; 102(42):15195-200. PubMed ID: 16210249
[TBL] [Abstract][Full Text] [Related]
10. Novel c-Myc-Targeting Compound
Sriratanasak N; Petsri K; Laobuthee A; Wattanathana W; Vinayanuwattikun C; Luanpitpong S; Chanvorachote P
Mol Pharmacol; 2020 Aug; 98(2):130-142. PubMed ID: 32487733
[TBL] [Abstract][Full Text] [Related]
11. Rabring7 degrades c-Myc through complex formation with MM-1.
Narita R; Kitaura H; Torii A; Tashiro E; Miyazawa M; Ariga H; Iguchi-Ariga SM
PLoS One; 2012; 7(7):e41891. PubMed ID: 22844532
[TBL] [Abstract][Full Text] [Related]
12. The histone deacetylase SIRT2 stabilizes Myc oncoproteins.
Liu PY; Xu N; Malyukova A; Scarlett CJ; Sun YT; Zhang XD; Ling D; Su SP; Nelson C; Chang DK; Koach J; Tee AE; Haber M; Norris MD; Toon C; Rooman I; Xue C; Cheung BB; Kumar S; Marshall GM; Biankin AV; Liu T
Cell Death Differ; 2013 Mar; 20(3):503-14. PubMed ID: 23175188
[TBL] [Abstract][Full Text] [Related]
13. c-IAP1 cooperates with Myc by acting as a ubiquitin ligase for Mad1.
Xu L; Zhu J; Hu X; Zhu H; Kim HT; LaBaer J; Goldberg A; Yuan J
Mol Cell; 2007 Dec; 28(5):914-22. PubMed ID: 18082613
[TBL] [Abstract][Full Text] [Related]
14. Novel ubiquitin-independent nucleolar c-Myc degradation pathway mediated by antizyme 2.
Murai N; Murakami Y; Tajima A; Matsufuji S
Sci Rep; 2018 Feb; 8(1):3005. PubMed ID: 29445227
[TBL] [Abstract][Full Text] [Related]
15. c-Myc is targeted to the proteasome for degradation in a SUMOylation-dependent manner, regulated by PIAS1, SENP7 and RNF4.
González-Prieto R; Cuijpers SA; Kumar R; Hendriks IA; Vertegaal AC
Cell Cycle; 2015; 14(12):1859-72. PubMed ID: 25895136
[TBL] [Abstract][Full Text] [Related]
16. Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7 gamma.
Bonetti P; Davoli T; Sironi C; Amati B; Pelicci PG; Colombo E
J Cell Biol; 2008 Jul; 182(1):19-26. PubMed ID: 18625840
[TBL] [Abstract][Full Text] [Related]
17. TRIB3 promotes MYC-associated lymphoma development through suppression of UBE3B-mediated MYC degradation.
Li K; Wang F; Yang ZN; Zhang TT; Yuan YF; Zhao CX; Yeerjiang Z; Cui B; Hua F; Lv XX; Zhang XW; Yu JJ; Liu SS; Yu JM; Shang S; Xiao Y; Hu ZW
Nat Commun; 2020 Dec; 11(1):6316. PubMed ID: 33298911
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cIAP1 as a strategy for targeting c-MYC-driven oncogenic activity.
Li H; Fang Y; Niu C; Cao H; Mi T; Zhu H; Yuan J; Zhu J
Proc Natl Acad Sci U S A; 2018 Oct; 115(40):E9317-E9324. PubMed ID: 30181285
[TBL] [Abstract][Full Text] [Related]
19. The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma.
Crawford LJ; Campbell DC; Morgan JJ; Lawson MA; Down JM; Chauhan D; McAvera RM; Morris TC; Hamilton C; Krishnan A; Rajalingam K; Chantry AD; Irvine AE
Oncogene; 2020 Jul; 39(27):5001-5014. PubMed ID: 32523091
[TBL] [Abstract][Full Text] [Related]
20. Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC.
Lankes K; Hassan Z; Doffo MJ; Schneeweis C; Lier S; Öllinger R; Rad R; Krämer OH; Keller U; Saur D; Reichert M; Schneider G; Wirth M
Mol Oncol; 2020 Dec; 14(12):3048-3064. PubMed ID: 33099868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
